Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Targovax ASA ( (GB:0RIS) ) has issued an update.
Circio Holding ASA has increased its share capital by NOK 70,516.20 through the issuance of 117,527 new shares at a nominal value of NOK 0.60, tied to the exercise and settlement of share options and restricted stock units under its long-term incentive programs. The move modestly dilutes existing shareholders but underscores the company’s use of equity-based incentives to align directors and employees with shareholder interests, with board members Damian Marron, Diane Mellett and Thomas Falck all increasing their direct holdings, subject to standard regulatory disclosure under EU and Norwegian securities rules.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing novel circular RNA expression technology for gene and cell therapies. Its proprietary circVec platform, developed by subsidiary Circio AB in Stockholm, is designed to deliver longer RNA half-life and significantly enhanced protein expression, targeting applications across genetic medicine, cell therapy and chronic disease therapeutics.
Average Trading Volume: 16,948,211
Current Market Cap: NOK2.09B
For detailed information about 0RIS stock, go to TipRanks’ Stock Analysis page.